Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

This pilot study tests a combination of chemotherapy, immunotherapy, and heat therapy (thermal therapy) given before surgery in women with HER2-negative breast cancer. Researchers want to see if adding heat treatment to standard chemotherapy and immunotherapy improves outcomes before surgery. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have been diagnosed with invasive HER2-negative breast cancer (either triple-negative or hormone receptor positive) - Your cancer is locally advanced (stage cT2–4N+M0) - You have not received any prior chemotherapy, radiation, or hormonal therapy for this cancer - Your heart, blood counts, and organ function are within acceptable ranges **You may NOT be eligible if...** - You have previously received any anti-cancer treatment - You have a serious heart condition (NYHA Grade II or above) - You have severe infections or other serious illnesses - You are pregnant or breastfeeding - You have had another cancer in the past 5 years (except certain cured skin or cervical cancers) Talk to your doctor to see if this trial is right for you.